![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.14 | -0.35% | 39.87 | 1,274 | 09:56:00 |
By Ian Walker
GSK said Friday that it has now sold 240 million shares in consumer healthcare business Haleon for 335 pence each, raising 804 million pounds ($1.01 billion), as first announced late Thursday.
The pharmaceutical giant said Thursday night that it was selling the shares via an accelerated bookbuild. The sale price is a 2.3% discount to Haleon's closing price of 342.85 pence on Thursday.
Following the sale GSK will continue to hold 955 million Haleon shares, or 10.3% of its issued share capital.
Haleon--which includes well-known brands such as Sensodyne and Voltaren--was formed in July 2019 between GSK and Pfizer via the merger of their consumer healthcare businesses into a new joint-venture company.
It was spun out and listed on the London Stock Exchange last July. Pfizer has a 32% shareholding in Haleon.
GSK and Pfizer have agreed not to sell any further Haleon shares for 60 days.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
May 12, 2023 02:32 ET (06:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions